BillionToOne, Inc.

BillionToOne, Inc., a next-generation molecular diagnostics company, announced that its management will participate in the William Blair 46th Annual Growth Stock Conference. The presentation is scheduled for Tuesday, June 2, 2026, from 12:40pm to 1:10pm Central Time. A live and archived webcast of the presentation will be accessible on the company's investor relations website.

BillionToOne, Inc. reported strong financial results for the first quarter of 2026, with revenue increasing by 83.8% year-over-year to $108.39 million. The company swung to a net income of $17.97 million, a significant improvement from a net loss of $3.99 million in the prior-year period. This performance was driven by substantial growth in both prenatal and oncology testing services, alongside an amendment to its partnership agreement with Johnson & Johnson.

BillionToOne, Inc. reported strong financial results for the first quarter ended March 31, 2026, with total revenue increasing 84% year-over-year to $108.4 million and achieving a net income of $18.0 million. The company also raised its full-year 2026 revenue guidance to a range of $450 million to $465 million, reflecting 48% to 52% growth over 2025. Additionally, BillionToOne launched Unity ConfirmTM, a new non-invasive prenatal confirmation assay.

BillionToOne, Inc. announced its plan to release financial results for the first quarter ended March 31, 2026. The results will be disclosed after the market closes on Wednesday, May 6, 2026. The company will also host a conference call and webcast on the same day at 4:30 PM Eastern Time to discuss the financial performance.